https://www.eurekalert.org/pub_releases/2021-07/esfm-psi070121.php
News Release 2-Jul-2021
ESMO World Congress on Gastrointestinal Cancer 2021
European Society for Medical Oncology
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021 (1). Further findings showed that cumulative relative chemotherapy dose was associated with survival so may explain the poorer survival that has been seen in obese patients receiving adjuvant chemotherapy for colorectal cancer. (2)
"Adjuvant chemotherapy is dosed according to a person's body surface area, which is calculated from their height and weight. But in obese patients (with a high body mass index (BMI), and who are more likely to have high BSAs), doses are often capped, or based on an idealised weight, because of concern that large doses might increase side-effects. This means that obese patients may receive proportionately lower doses of chemotherapy" reported lead author Corinna Slawinski, from the Division of Cancer Sciences, University of Manchester, UK. Congress on Gastrointestinal Cancer 2021
•••••
No comments:
Post a Comment